News

For the third day in a row, shares of big pharma bellwether Pfizer (NYSE: PFE) are heading higher -- which is kind of curious. Just last week, Pfizer issued downbeat guidance for the year ahead. But

The success of drug developers hinges on regulatory approvals for their medications. Considering that, it was hardly surprising that Pfizer (NYSE: PFE) stock had a good Monday on the market

Per updated guidance for its upcoming 2024 fiscal year, issued on Dec. 13, Pfizer (NYSE: PFE) has a bumpy road ahead -- at least for now. Amidst rapidly weakening coronavirus product revenue and

Many investors will likely be wearing big smiles as 2023 winds down. The S&P 500 is on track to deliver a gain of over 20% and could hit an all-time high. The Nasdaq-100 has soared more than 50% and

Earlier in the pandemic, Pfizer (NYSE: PFE) stood out as an earnings and stock-market star thanks to its leading coronavirus vaccine and treatment. But these days, those products are weighing on

Having at least $1 million in the bank by retirement has long been a popular goal, but it isn't easy to accomplish. One of the best ways to do so is to invest in stocks, and the earlier one starts

Don't have a lot of time to follow stocks and want some safe options for your portfolio? Three stocks that are big names within their respective industries and that can make for excellent long-term

Earlier in the pandemic, coronavirus products boosted the revenue and the stock prices of companies selling those products. But these days, those products actually have done just the opposite

When dividend stocks crash in value, that sends their yields up in the opposite direction. But there can be danger for investors who load up on a stock just because its yield is high.

Before buying

Pfizer (NYSE: PFE) was a top performer when the U.S. government was shoveling COVID-related revenue in its direction. Unfortunately, the past year hasn't been nearly as kind. The former high-flying

Shares of Pfizer (NYSE: PFE) were sinking 8.3% lower as of 11:25 a.m. ET on Wednesday. The sharp sell-off came after the drugmaker provided its guidance for full-year 2024.

Pfizer expects 2024

The stock market looked ready to keep climbing early Wednesday, even as investors were largely in wait-and-see mode during the last day of the Federal Reserve's current monetary policy meeting

With AbbVie (NYSE: ABBV) reporting on Nov. 30 that it plans to acquire ImmunoGen, (NASDAQ: IMGN) a biotech developing antibody-drug conjugate (ADC) therapies for various cancers, it's clear that the

The stock market has climbed this year, but that doesn't mean the bargains are over. Many stocks missed out on the rally even though their long-term outlooks remain solid. And these are the stocks

I have always stated that stocks should not be bought just because they trade at a 52-week low. A new 52-week low does not make a particular stock cheap.

In today's video I will look at three

Shares of Pfizer (NYSE: PFE) have been in an endless tailspin this year -- now down more than 40%. The top drugmaker can't seem to catch a break. Revenue from its COVID-19 products is down big, and

On Dec. 1, Pfizer (NYSE: PFE) reported some less-than-great news to investors. In short, its latest attempt at developing a drug to compete with Novo Nordisk's blockbuster medicine Ozempic will not

Stocks have rallied this year, but one of the world's most famous pharma companies didn't join the party. Pfizer (NYSE: PFE), known for its billion-dollar coronavirus products -- the vaccine

As the year comes to an end, it's time to think about which stocks to sell for tax-loss harvesting. One stock I'm considering letting go is pharma giant Pfizer (NYSE: PFE). The company's shares have

Shares of Pfizer (NYSE: PFE) were sinking 4.4% lower as of 11:10 a.m. ET on Friday after falling as much as 7.1% earlier in the morning. The sell-off came after the company announced that it's

Pfizer's (NYSE: PFE) stock performance has been disappointing this year (down 38%). The company has faced multiple challenges, such as declining revenues from COVID-19 products, looming patent

Last year, pharmaceutical giant Pfizer (NYSE: PFE) reported the highest revenue it had ever had in a single calendar year. But in 2023, the drugmaker has substantially underperformed the market, and

When it comes to gene-editing companies on the cutting edge, Beam Therapeutics (NASDAQ: BEAM) is keen to be one of the leaders. While it's a bit of a laggard in terms of its pipeline's maturity

AbbVie (NYSE: ABBV) and Pfizer (NYSE: PFE) are makers of two of the world's top-selling pharmaceutical products. AbbVie's immunology drug Humira brought in peak sales of more than $21 billion, while

Both Pfizer (NYSE: PFE) and Novo Nordisk (NYSE: NVO) can claim to investors that plenty more growth is on the way. With new markets beckoning and multi-year strategic plans in full swing, both of